1. Behrman R, FDA news release [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291232.htm [Accessed 2012 Feb 9]
2. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Accessed 2012 Feb 9]
3. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf [Accessed 2012 Feb 9]
4. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry: biosimilars — questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf [Accessed 2012 Feb 9]
5. CHMP. Guideline on similar biological medicinal products. CHMP/437/04 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf [Accessed 2012 April 2]